37 results about "Somatic antigen" patented technology

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This disclosure provides an anti-5T4 antigen-binding domain that can be incorporated into antibodies and receptors, including a bispecific anti-5T4 antibody, a biparatopic anti-5T4 antibody, and its antibody-drug conjugate, comprising a first antigen-binding domain that specifically binds to a first 5T4 epitope, a second antibody-antigen-binding domain that specifically binds to a second 5T4 epitope that is not identical to the first 5T4 epitope (the first antigen-binding domain is operably linked to the second antigen-binding domain), and a chemotherapeutic agent. This disclosure further provides methods for using it for the treatment of cancer.

The application discloses a kind of nanomaterial and its preparation method and application, the nanomaterial includes exosome and liposome;The exosome expresses immune checkpoint, the exosome is derived from brain glioma cell;The liposome is loaded with I type photosensitizer.The application is by PDT, immune checkpoint and brain glioma cell exosome antigen three tubes simultaneously to remodel tumor local immune microenvironment, greatly improve the efficiency of cancer immunotherapy, can activate strong anti brain glioma immune response and overcome immune escape.

Anti-IGF1R (insulin-like growth factor 1 receptor) antibodies, antigen-binding fragments, and their uses are provided.

The application discloses a mechanism-driven nanobody-antigen binding prediction method and system, relates to the technical field of bio-information processing and artificial intelligence, and inputs amino acid sequences of nanobodies and antigens into a prediction system for processing, and a construction process of the prediction system comprises the following steps: after an encoder encodes the amino acid sequences of the nanobodies and the amino acid sequences of the antigens, global features and local features of respective complementarity determining regions are extracted and fused to obtain nanobody fusion features and antigen fusion features, and the nanobody fusion features and the antigen fusion features are subjected to global average pooling to obtain an encoder feature of the nanobodies and an encoder feature of the antigens; a combination prediction model models the interaction between the encoder feature of the nanobodies and the encoder feature of the antigens through Hadamard product modeling, generates an interaction feature, and predicts a combination probability based on the interaction feature. Through the cooperative work of the mechanism-driven encoder and the prediction system, high-precision and high-efficiency nanobody-antigen binding prediction is realized.

This invention discloses a blow-type sampling viral antigen detection kit and its usage method, including a sampler, a blow nozzle, a detection working column, and a equilibration liquid dropper. Sampling is performed by blowing air, a simple sampling method that reduces the probability of sampling errors in untrained individuals. Equilibration liquid is dripped into the funnel-shaped opening of the sampler's receiving tank through the equilibration liquid dropper, continuously eluting the biological sample. The operation is simple and effective. The equilibration liquid, along with the eluted biological sample, enters a colloidal gold filter. The colloidal gold is re-dissolved, captures and labels the viral antigen in the solution. The labeled antigen then enters an antibody filter impregnated with specific antibodies, where it is captured by those antibodies, forming a conjugate of antibody, antigen, and colloidal gold microparticles. A large number of these conjugate microparticles aggregate on the filter membrane above the absorbent cotton column, resulting in color development. The sample elution step is simple, the sampling method is reliable, and the detection and colorimetric observation are easy to perform, making it convenient for the general public to use.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, or example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.

To provide reliable positive and negative IHC controls that are highly sensitive, specific, and adaptable to a wide range of targets, including targets for which no suitable biological controls exist.SOLUTION: Synthetic controls include a solid antigen / carrier protein gel comprising purified antigen (e.g., in a known amount) and a carrier protein, such as a serum albumin protein (e.g., a serum albumin protein), an egg white protein or a mixture of egg white proteins, gelatin, or polylysine. In some embodiments, the purified antigen is cross-linked to a carrier protein in a solid antigen / carrier protein gel.SELECTED DRAWING: Figure 3-1

This invention relates to a system and method for assaying the presence of high molecular weight analytes such as proteins, antibodies, antigens, and receptors, using a targeted two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS / MS) system, optionally combined with affinity capture. [Solution] In some embodiments, the system is partially or fully automated. In some embodiments, the system may enable the detection of protein biomarkers (e.g., antibodies or antigens) from clinical or nonclinical biological tissue or fluid samples in the range of pg / mL to ng / mL.

Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen.

The invention relates to a nanometer antibody and antigen interaction prediction method and device, computer equipment and a storage medium. The method comprises the following steps: obtaining a to-be-detected nano antibody sequence and a to-be-detected antigen sequence; according to the to-be-detected nano-antibody sequence and the to-be-detected antigen sequence, utilizing a first embedding generator to respectively generate a nano-antibody embedding vector and an antigen embedding vector; according to the to-be-detected nano-antibody sequence and the to-be-detected antigen sequence, generating a nano-antibody antigen pair embedding vector by using a second embedding generator; fusing the nano-antibody embedded vector and the nano-antibody antigen pair embedded vector to obtain a nano-antibody fusion feature, and fusing the antigen embedded vector and the nano-antibody antigen pair embedded vector to obtain an antigen fusion feature; and predicting the interaction between the to-be-detected nano-antibody sequence and the to-be-detected antigen sequence according to the nano-antibody fusion characteristics and the antigen fusion characteristics. By adopting the method, the accuracy of predicting the interaction between the nano antibody and the antigen can be improved.

This invention discloses a triple inactivated vaccine containing Mycoplasma gallisepticum, Mycoplasma synoviae, and Infectious Laryngotracheitis in chickens, its preparation method, and its application. The technical solution includes inactivated Mycoplasma gallisepticum antigen, inactivated Mycoplasma synoviae antigen, and inactivated Infectious Laryngotracheitis Virus gD protein; wherein the inactivated Mycoplasma gallisepticum antigen is prepared from Mycoplasma gallisepticum strain YBMG1, and the preservation number of Mycoplasma gallisepticum strain YBMG1 is CCTCC M 20261107. This invention rationally combines Mycoplasma gallisepticum antigen, Mycoplasma synoviae antigen, and chicken infectious laryngotracheitis virus gD protein, and uses saponin as an immune enhancer. This effectively reduces the interference of chicken infectious laryngotracheitis virus gD protein on the immune response of Mycoplasma gallisepticum and Mycoplasma synoviae, and the effect is significantly better than other polysaccharide or polypeptide immune enhancers, thereby achieving simultaneous prevention and control of Mycoplasma gallisepticum disease, Mycoplasma synoviae disease, and chicken infectious laryngotracheitis.

The invention relates to the technical field of monoclonal antibodies, in particular to a complement C1q monoclonal antibody and application thereof, the heavy chain sequence of the complement C1q monoclonal antibody is shown as SEQ ID NO: 1, and the light chain sequence of the complement C1q monoclonal antibody is shown as SEQ ID NO: 2. The complement C1q monoclonal antibody provided by the invention has high specificity and high sensitivity, can maintain stability under various experimental conditions, is not easily interfered by external factors, and ensures the accuracy and reliability of a detection result. The complement C1q monoclonal antibody provided by the invention can be used in the field of in vitro diagnosis and detection, and realizes rapid, efficient and high-sensitivity clinical detection of the complement C1q antigen.

The application belongs to the technical field of biological medicine, and specifically discloses a method for applying induced pluripotent stem cell-derived exosomes in a DC vaccine. The application provides a preparation method of a tumor vaccine, which comprises the following steps: using induced pluripotent stem cell exosomes to sensitize DC cells to obtain the tumor vaccine. The induced pluripotent stem cell-derived exosomes provided by the application have the characteristics of uniform particle size, low toxicity, good cell compatibility, high yield and the like. The DC vaccine provided by the application has the abilities of tumor treatment, tumor prevention and tumor metastasis inhibition, and has low toxicity, and is a simple, practical and applicable technology and method. The application solves the problems of tumorigenicity, large volume, interception by lung and other tissues, difficulty in being taken up by DC, only tumor prevention ability and the like of the existing induced pluripotent stem cell vaccine, and solves the problem of lack of antigen source in the construction of the DC vaccine.

The invention belongs to the technical field of veterinary biology, and discloses an escherichia coli NK2 strain and application thereof in preparation of a mycoplasma hyopneumoniae culture medium. According to the invention, an Escherichia coli NK2 is screened, and the preservation number of the Escherichia coli NK2 is CCTCC (China Center For Type Culture Collection) NO: M20252722. The mycoplasma hyopneumoniae high-efficiency culture medium is prepared by the applicant by taking fermentation supernate of an endotoxin-removed escherichia coli NK2 strain as an auxiliary culture medium, the growth speed of the mycoplasma hyopneumoniae can be increased by adding the auxiliary culture medium, the culture time of the mycoplasma hyopneumoniae can be shortened, and the yield of the mycoplasma hyopneumoniae can be increased. Therefore, generation of aged bacteria is reduced, the viable count during culture harvesting is remarkably increased, the thallus antigen content during culture harvesting is remarkably improved, and the method has the advantages of being convenient to use, easy to obtain, low in cost, high in economic benefit and the like.

This invention pertains in general to, for example, T cell and NK cells for use as cell therapy products, for example in the treatment of a tumor in a patient suffering from cancer. The invention provides heterologous nucleic acids encoding cell surface expressed antigen receptors under the control of a promoter that is induced when the antigen receptor is activated, for example upon interaction between the antigen receptor and its cognate binding partner (antigen) expressed on a (tumor) cell.

The present disclosure relates to a fibrin (ogen) degradation product detection kit and its preparation and application. The detection method of the kit is magnetic particle chemiluminescence immunoassay, and the reagent composition comprises a first reagent, a second reagent, a third reagent and its calibrator, and a quality control product. The third reagent is a magnetic particle coated with an antibody, which can bind to the analyte in the sample; the first reagent is a sample diluent; the second reagent is an enzyme-labeled antibody reagent, which can bind to the analyte in the sample to form an antibody-antigen-antibody sandwich complex. The kit of the present disclosure realizes high-speed and high-sensitivity detection, and is mainly used for the auxiliary diagnosis of primary and secondary fibrinolysis hyperfunction related diseases in clinical practice.

An immunomodulatory nanoparticle vaccine carrier protein and its application. This invention uses duck hepatitis B virus core antigen (DHBc) as a base, fuses and expresses the SpyCatcher003 sequence to construct DHBc-SpyCatcher (DHBc-SC) virus-like particles with self-assembly capability, and efficiently expresses them in *E. coli*. When DHBc-SC virus-like particles are mixed with heterologous monomeric antigens containing SpyTag, they can spontaneously couple to form virus-like particles displaying the heterologous antigen, significantly enhancing the immunogenicity of the heterologous antigen.

The invention discloses a self-adaptive sensing method for network security of a power system based on an immune principle, which introduces a complete dynamic response mechanism of a biological immune system into the field of network security of the power system for the first time, and realizes self-adaptive recognition of network threats by constructing a quantitative mapping model of detector-antibody-antigen. Antibody concentration is created as a unified quantitative index, and accurate mathematical mapping from microcosmic immune dynamics to macroscopic safety risks is established; a perception-evaluation-prediction three-layer perception architecture is provided, and a grey Markov model suitable for a small sample and poor information system is adopted, so that the prediction bottleneck of high randomness of network security data is effectively overcome; and finally, multi-dimensional visual fusion is carried out through a GIS to form a closed loop of perception, evaluation, prediction and decision making. According to the method, the passive, static and qualitative defense mode of a traditional model is fundamentally changed, and the crossing of the network security of the power system from static protection to dynamic immunity is realized.

The present invention provides an antibody and an antigen-binding fragment (e.g., a human antibody) that specifically bind to human IL2 receptor gamma (IL2Rγ). A method for treating or preventing a disease mediated by IL2Rγ (e.g., graft-versus-host disease) using the antibody and the fragment is also provided along with a method for preparing the antibody and the fragment.

The application provides a nanocarrier, which comprises a nanosphere core and a nanosphere shell, wherein the nanosphere core comprises squalene; the nanosphere shell comprises a surfactant; and the nanosphere core and the nanosphere shell are combined through hydrophobic interaction. The nanocarrier prepared by the application can continuously regulate the surface properties, and the vaccine prepared by the nanocarrier has the advantages of high efficiency, low toxicity, convenience in preparation and storage, and the like. The nanocarrier overcomes the defects of low antigen-specific T cell induction efficiency of a traditional antigen carrier.

The present invention relates to the technical field of biomedicine, in particular to the field of cell therapy, specifically to a CLL1-binding nanobody or an antigen-binding fragment thereof, and further to a STAR comprising the CLL1-binding nanobody or the binding fragment thereof. The present invention further relates to a STAR binding to both CLL1 and LILRB4 targets, and uses of a STAR complex, cell and pharmaceutical composition comprising the STAR in the treatment and / or prevention of tumors.

The present disclosure provides anti-5T4 antigen binding domains that can be incorporated into antibodies and recipients, including bispecific anti-5T4 antibodies, biparatopic anti-5T4 antibodies, and antibody-drug conjugates thereof, the antibody-drug conjugates comprising: a first antigen binding domain that specifically binds to a first 5T4 epitope; a second antibody antigen binding domain that specifically binds to a second 5T4 epitope different from the first 5T4 epitope; wherein the first antigen binding domain is operably linked to the second antigen binding domain; and a chemotherapeutic agent. The disclosure further provides methods of using the same for treating cancer.

This invention relates to the field of monoclonal antibody technology, and in particular to a complement C1q monoclonal antibody and its applications. The heavy chain sequence is shown in SEQ ID NO:1, and the light chain sequence is shown in SEQ ID NO:2. The complement C1q monoclonal antibody of this invention exhibits high specificity and high sensitivity, maintains stability under various experimental conditions, and is not easily affected by external factors, ensuring the accuracy and reliability of the detection results. This complement C1q monoclonal antibody can be used in the field of in vitro diagnostic detection, achieving rapid, efficient, and highly sensitive clinical detection of the complement C1q antigen.

The application belongs to the technical field of antigen protein and antibody preparation and discloses a Linopneus Genomic Differentiation Factor-8 / 11 polyclonal antibody, antigen protein and a preparation method thereof. The application obtains recombinant expression of the Linopneus Genomic Differentiation Factor-8 / 11 antigen protein, obtains the Linopneus Genomic Differentiation Factor-8 / 11 polyclonal antibody after immunizing mice, and provides an advantageous tool for the research on the Linopneus Genomic Differentiation Factor-8 / 11 protein level. The application also successfully obtains a Linopneus Genomic Differentiation Factor-8 / 11 antigen protein recombinant expression vector, and can obtain the Linopneus Genomic Differentiation Factor-8 / 11 antigen protein. The application also provides a Linopneus Genomic Differentiation Factor-8 / 11 gene coding region full sequence, fills the blank of related research, and the primer pair provided by the application can amplify the above Linopneus Genomic Differentiation Factor-8 / 11 gene coding region full sequence through PCR, and can be used for other related research.

Provided herein are anti-VEGF-A (vascular endothelial growth factor A) antibodies, antigen-binding fragments, and the uses thereof.

This invention belongs to the field of biomedical technology, specifically relating to a kit for detecting brucellosis and its application. The kit includes an enzyme-linked immunosorbent assay (ELISA) plate coated with a capture antibody, HRP-labeled antibody, antigen standards, washing buffer, chromogenic solution, and stop solution. The heavy chain amino acid sequence of the anti-CTSC protein monoclonal antibody CTSC-1 in the capture antibody is shown in SEQ ID NO.1, and the light chain amino acid sequence is shown in SEQ ID NO.2. The heavy chain amino acid sequence of the anti-CTSC protein monoclonal antibody CTSC-2 in the HRP-labeled antibody is shown in SEQ ID NO.3, and the light chain amino acid sequence is shown in SEQ ID NO.4. The kit for detecting brucellosis provided by this invention has high specificity, can specifically detect the content of CTSC protein in urine, has high sensitivity, and has good application prospects.